Ardelyx Stock News

Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported b

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the Cowen and Company 40th Annual Health Care Conference at 8:00 a.m. ET

Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will present at the 9th Annual SVB Leerink Global Healthcare Conference at 3:30 p.m. ET o

Gainers Stealth BioTherapeutics, Inc. (NASDAQ: MITO) stock increased by 38.4% to $3.10 during Tuesday's pre-market session. According to the most recent rating by H...

Upgrades Northland changed the rating for Casa Systems Inc (NASDAQ: CASA) from Market Perform to Outperform. For the third quarter, Casa Systems had an EPS of ($0.03),...

Ardelyx (NASDAQ:ARDX) initiated with Buy rating and $13 (75% upside) price target at Citigroup. Shares up 5% premarket.I-Mab (NASDAQ:IMAB) initiated with Buy rating and $17.93 price target at China

Upgrades Chardan Capital upgraded the stock for Adverum Biotechnologies Inc (NASDAQ: ADVM) from Neutral to Buy. Adverum Biotechnologies earned ($0.25) in the third...

With its first FDA approval in hand, a second, more lucrative indication looms on the horizon.